Press Release

Repair of mitochondrial recycling defect linked to Parkinson’s disease

Published on 3 August 2021

Treating mice that have a Parkinson’s disease-causing mutation with a small molecule compound restores the removal of damaged mitochondria from their brain cells, shows a study published today in eLife.

On this page
SLS building at dusk

Treating mice that have a Parkinson’s disease-causing mutation with a small molecule compound restores the removal of damaged mitochondria from their brain cells, shows a study published today in eLife.

The findings may help explain what goes wrong in dopamine-producing brain cells in people with mutations that cause Parkinson’s disease.

Parkinson’s disease is caused by the progressive loss of brain cells that produce dopamine. This causes the hallmark symptoms of the disease, including tremors, rigid movements, sleep problems and dementia.

“Scientists believe the death of these cells in people with Parkinson’s disease is caused, in part, by the failure of a quality control mechanism that removes damaged energy-producing structures in the cells called mitochondria,” explains first author Dr Francois Singh, Postdoctoral Research Assistant at the University of Dundee’s Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC PPU). “This failure to recycle damaged mitochondria is detrimental to the health of brain cells.”

To learn more, Dr Singh and colleagues teamed up with scientists from Dundee’s Division of Signal Transduction Therapy, a consortium of academia and pharmaceutical companies. Together they used cutting-edge techniques to observe mitochondria recycling in the brains of mice that have the most common Parkinson’s disease-causing mutation in a gene called LRRK2.

Their experiments showed that damaged mitochondria are not efficiently removed in the animals’ dopamine-producing brain cells, and that damaged components in other types of brain cells are recycled. This may explain why dopamine-producing brain cells are selectively lost in Parkinson’s disease and why the symptoms are all linked to a lack of dopamine.

The mutation in the LRRK2 gene results in the production of a hyperactive version of the protein. Given this, the team treated the mice with a small molecule that inhibits the hyperactive protein and found that it restored mitochondria recycling in the animals’ dopamine-producing brain cells.

The authors say these results are an exciting step forward in the quest to understand mechanisms responsible for this currently incurable disease. These results should help drive and focus research in this area.

“Not only have we discovered new biology, but we have also shown that an LRRK2 inhibitor can rescue a mitochondrial defect related to Parkinson’s disease,” added senior author Dr Ian Ganley, MRC Investigator and Scientific Programme Leader at MRC PPU. “These findings highlight the significant benefit of academic-industrial collaborations that will hopefully accelerate the development of new treatments for Parkinson’s disease.”

Notes to editors

About eLife

eLife is a non-profit organisation created by funders and led by researchers. Their mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. They publish work of the highest standards and importance in all areas of biology and medicine, including Cell Biology and Neuroscience, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

To read the latest Cell Biology research published in eLife, visit https://elifesciences.org/subjects/cell-biology.

And for the latest in Neuroscience, see https://elifesciences.org/subjects/neuroscience.

Enquiries

Grant Hill

Press Officer

+44 (0)1382 384768

G.Hill@dundee.ac.uk
Story category Research